Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Key Inclusion Criteria:

1. Currently participating in a BeiGene-sponsored eligible parent study

2. Fulfills treatment criteria specified in the parent study protocol

3. In the opinion of the investigator, the participant will continue to benefit fromand tolerate any of the parent study treatments.

4. The first dose of study treatment in the LTE study will be received within thetreatment interruption period allowed by the parent study:

5. "Treatment interruption" (unplanned pause in study treatment) and "treatmentbreak" (planned stop of study therapy) are not interchangeable. Restartingstudy treatment beyond the interruption period allowed by the parent study orafter a treatment break will be determined by the investigator and the sponsor.Participants who have not restarted treatment within 1 year of starting atreatment break must discontinue treatment.

Specific Inclusion Criteria for Participants Who Continue Survival Follow-up Only in the Extension Study:

1. Currently participating in a BeiGene-sponsored eligible parent study in the survivalfollow-up portion

2. Parent study plans to have survival analysis

Key Exclusion Criteria:

1. Permanently discontinued from all investigational drugs in the parent study due tounacceptable toxicity, noncompliance with study procedures, or withdrawal of consent

2. Have uncontrolled active systemic infection or recent infection requiring parenteralantimicrobial therapy prior to the start of the extension study

3. Have a life-threatening illness, medical condition, or organ system dysfunction thatin the investigator's opinion, could compromise the participant's safety, interferewith the absorption or metabolism of investigational drugs, or put the studyoutcomes at undue risk

4. Underwent treatment with any systemic anticancer treatment (other than treatmentpermitted in the parent study) during the time between the last treatment in theparent study and the first dose of study treatment in the LTE study

5. Pregnant or lactating women

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.